ANTENGENE CORPORATION LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.83 HKD | -3.49% |
|
-12.63% | -58.50% |
| Sales 2023 | 67.3M 9.3M 72.81M | Sales 2024 * | 141M 19.54M 153M | Capitalization | 518M 71.51M 560M |
|---|---|---|---|---|---|
| Net income 2023 | -581M -80.25M -629M | Net income 2024 * | -475M -65.61M -514M | EV / Sales 2023 | 18.2 x |
| Net cash position 2023 | 986.68 136.29 1.07K | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 3.66 x |
| P/E ratio 2023 |
-1.93
x | P/E ratio 2024 * |
-1.04
x | Employees | 201 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 53.36% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.49% | ||
| 1 week | -12.63% | ||
| Current month | -17.00% | ||
| 1 month | -26.55% | ||
| 3 months | -40.71% | ||
| 6 months | -36.64% | ||
| Current year | -58.50% |
1 week
0.81
0.95
1 month
0.811.14
Current year
0.812.00
1 year
0.812.96
3 years
0.8120.30
5 years
0.8122.50
10 years
0.8122.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Ming Mei
CEO | Chief Executive Officer | 58 | 18-08-27 |
| Director of Finance/CFO | 42 | - | |
Xiao-Jing Zhang
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rafael Fonseca
BRD | Director/Board Member | 57 | 23-04-13 |
Jian Ming Mei
CEO | Chief Executive Officer | 58 | 18-08-27 |
Yiteng Liu
COO | Chief Operating Officer | 40 | 18-11-01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.40% | 4 M€ | -27.92% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.83 | -3.49% | 161,727 |
| 24-04-18 | 0.86 | -3.37% | 182,000 |
| 24-04-17 | 0.89 | -2.20% | 390,000 |
| 24-04-16 | 0.91 | -2.15% | 75,500 |
| 24-04-15 | 0.93 | -2.11% | 39,000 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT
More quotes
Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.7672
CNY
Average target price
1.666
CNY
Spread / Average Target
+117.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.50% | 71.51M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +0.18% | 13.28B | |
| +19.90% | 10.85B |
- Stock Market
- Equities
- 6996 Stock
